A novel small molecule, BT317, is derived from coumarinic compound 4 (CC4) using structure-activity modeling and is found to inhibit both LonP1 and CT-L proteasome activity and subsequently induce ROS accumulation and autophagy-dependent cell death in high-grade IDH1 mutated astrocytoma lines. In vitro, BT317 also has enhanced synergy with the commonly used chemotherapeutic temozolomide (TMZ).
MedKoo Cat#: 150051
Name: BT317
CAS#: N/A
Chemical Formula: C16H10ClNO4
Exact Mass: 315.0300
Molecular Weight: 315.71
Elemental Analysis: C, 60.87; H, 3.19; Cl, 11.23; N, 4.44; O, 20.27
The following data is based on the product molecular weight 315.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
